H. Lundbeck A/S held its Annual General Meeting on 20 April

At the general meeting the report by the Supervisory Board and the Annual Report
were approved, and the Supervisory Board and Executive Management were
discharged from liability.

The general meeting approved the dividend of DKK 602 million or DKK 3.07 per
share of DKK 5 nominal value proposed by the Supervisory Board.

Per Wold-Olsen, Thorleif Krarup, Peter Kürstein, Mats Pettersson, Jes Østergaard
and Egil Bodd were all re-elected to the Supervisory Board. Immediately after
the general meeting, the Supervisory Board elected Per Wold-Olsen Chairman and
Thorleif Krarup Deputy Chairman of the Supervisory Board.

After having elected its Chairman and Deputy Chairman, the Supervisory Board
appointed members for the Audit Committee, the Remuneration Committee and
the recently established Scientific Committee.

Peter Kürstein, Egil Bodd and Thorleif Krarup were re-elected as members of the
Audit Committee. Per Wold-Olsen, Jes Østergaard and Mats Pettersson were
re-elected as members of the Remuneration Committee. Egil Bodd, Jes Østergaard
and Mats Pettersson were re-elected as members of the Scientific Committee.

The Supervisory Board of H. Lundbeck A/S will hereafter comprise:

- Per Wold-Olsen

- Thorleif Krarup

- Peter Kürstein

- Mats Pettersson

- Jes Østergaard

- Egil Bodd

- Mona Elster (employee representative)

- Jørn Møller Mayntzhusen (employee representative)

- Kim Rosenville Christensen (employee representative)

Deloitte Statsautoriseret Revisionsaktieselskab was re-appointed as the
company's auditor.

The proposed amendments to the Articles of Association by the Supervisory Board
based on the new Danish Companies Act and as a result of a general update were
adopted.

The Supervisory Board was authorised until the next annual general meeting to
let the company acquire treasury shares with a total nominal value of up to 10%
of the share capital at a purchase price of the shares in question, that may not
deviate by more than 10% from the price quoted on the Nasdaq OMX Copenhagen A/S
on the date of acquisition.

Supervisory Board

The content of this release will have no influence on the Lundbeck Group's
financial result for 2010.

Lundbeck contacts

Investors: Media:

Jacob Tolstrup Mads Kronborg

Vice President, IR & Communication Media Relations Manager

+45 36 43 30 79 +45 36 43 28 51

Palle Holm Olesen

Chief Specialist, Investor Relations

+45 36 43 24 26

Magnus Thorstholm Jensen

Investor Relations Officer

+45 36 43 38 16

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improve the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose Lundbeck is
engaged in the research and development, production, marketing and sale of
pharmaceuticals across the world, targeted at disorders like depression and
anxiety, schizophrenia, insomnia, Huntington's, epilepsies, Alzheimer's and
Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and
employs today approximately 5,900 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders. In 2009,
the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.

[HUG#1406973]

H. Lundbeck A/S held its Annual General Meeting on 20 April 2010 at the company's registered office

Attachments